Patent revocations in India may spread to other regions (or not) say legal experts
This article was originally published in Scrip
Patent revocations in a string of high-profile cases in India in 2012, including those concerning Pfizer’s Sutent (sunitinib malate) and Roche’s Pegasys (pegylated interferon alfa-2a) may be factored in as important reference points by other developing nations in future, some legal experts warn.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.